After buying back $30 million in stock over the past 12 months, the company is now planning a $10 million stock buyback.
Amylyx Pharmaceuticals has just one drug in its pipeline -- but it's for ALS, and the available treatments for that disease leave much to be desired.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results